--- title: "Mangoceuticals | 10-K: FY2025 Revenue: USD 456.02 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/281349211.md" datetime: "2026-04-01T10:35:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281349211.md) - [en](https://longbridge.com/en/news/281349211.md) - [zh-HK](https://longbridge.com/zh-HK/news/281349211.md) --- # Mangoceuticals | 10-K: FY2025 Revenue: USD 456.02 K Revenue: As of FY2025, the actual value is USD 456.02 K. EPS: As of FY2025, the actual value is USD -2.17. #### Segment Revenue - Revenue for Mangoceuticals, Inc. was $456,021 in 2025, a decrease from $615,873 in 2024, primarily due to issues with the transition and migration to a new telehealth platform . #### Operational Metrics - **Cost of Revenues:** - Cost of revenues was $54,422 in 2025, down from $93,296 in 2024, attributed to fluctuations in service usage and delivery costs . - Cost of revenues - related party (amounts paid to Epiq Scripts) increased to $151,213 in 2025 from $142,613 in 2024, due to increased cost of goods from the related party pharmacy . - **Gross Profit:** - Gross profit was $250,386 in 2025, compared to $379,964 in 2024 . - **Operating Expenses:** - General and Administrative Expenses increased to $3,756,373 in 2025 from $3,000,571 in 2024, mainly due to consulting and accounting expenses, offset by reductions in software, legal, and travel . - Salary and Benefits increased to $1,348,051 in 2025 from $1,063,781 in 2024, due to the engagement of new management and staff employees . - Advertising and Marketing decreased to $822,860 in 2025 from $1,478,663 in 2024, related to a reduction in efforts while focusing on the website re-launch . - Investor Relations increased significantly to $1,561,206 in 2025 from $453,749 in 2024, due to expanded efforts to raise public awareness . - Stock-Based Compensation increased to $10,794,245 in 2025 from $2,355,193 in 2024, reflecting greater use of equity-based incentives and higher stock prices . - Total Operating Expenses totaled $18,282,735 in 2025, compared to $8,351,957 in 2024 . - **Loss from Operations:** - Loss from operations was -$18,032,349 in 2025, compared to -$7,971,993 in 2024 . - **Other (Income) Expense:** - Interest Expense increased to $103,513 in 2025 from $13,700 in 2024, due to accrued interest on notes payable . - Amortization of Intangible Assets was $1,122,639 in 2025, up from $721,533 in 2024 . - Impairment of License Agreement was recognized at $1,239,942 in 2025 . - Loss from Settlement totaled $125,624 in 2025 due to legal settlements . - Loss from Debt Extinguishment - Related Parties was $19,388 in 2025 . - **Net Loss:** - Net loss for 2025 was -$20,643,455, an increase of $11,823,899 from -$8,707,226 in 2024, primarily due to decreased revenue and increased general and administrative expenses, stock-based compensation, and investor relations expenses . #### Financial Position Metrics - **Cash and Cash Equivalents:** Increased to $1,486,338 in 2025 from $58,653 in 2024, mainly due to financing activities . - **Working Capital:** Positive working capital of $0.6 million in 2025, compared to a working capital deficit of -$1.3 million in 2024 . - **Total Assets:** Total assets were $16,089,573 in 2025, compared to $15,370,511 in 2024 . - **Total Liabilities:** Total liabilities were $890,568 in 2025, compared to $1,425,463 in 2024 . - **Accumulated Deficit:** Accumulated deficit was -$40,647,480 in 2025, compared to -$20,004,486 in 2024 . - **Intangible Assets (Acquired Patents and License, Net):** Intangible assets were $14,232,484 in 2025, compared to $15,232,617 in 2024, after accounting for an impairment of $1,239,942 on the license agreement . #### Cash Flow - **Operating Activities:** Net cash used in operating activities was -$5,850,255 in 2025, primarily due to the net loss, offset by non-cash items like stock-based compensation, amortization, and impairment . In 2024, net cash used was -$4,863,776 . - **Investing Activities:** There was no net cash used in investing activities in 2025, while in 2024, net cash provided by investing activities was $65,000 from the sale of assets . - **Financing Activities:** Net cash provided by financing activities was $7,270,855 in 2025, mainly from proceeds from common stock sales, warrant exercises, subscription collection, Series B Convertible preferred stock sales, borrowings from the CEO, and a third-party note payable . In 2024, net cash provided was $4,128,268 . #### Outlook / Guidance Mangoceuticals, Inc. anticipates needing additional funding for the next 12 months to maintain current operations and cover public company costs, potentially through debt or equity offerings that may dilute existing shareholders . The company plans an aggressive growth strategy by expanding operations through marketing, technology enhancements, new product development, and strategic acquisitions, funding permitting . The Board of Directors is also evaluating potential strategic alternatives, including mergers, acquisitions, and divestitures, to maximize shareholder value, though without a definitive timeline or assurance of a specific outcome . ### Related Stocks - [MGRX.US](https://longbridge.com/en/quote/MGRX.US.md) ## Related News & Research - [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md) - [Home Depot Was Once My Greatest Investment, But Now It's a Flaming Mess](https://longbridge.com/en/news/286951517.md) - [08:45 ETThe Jed Foundation (JED) Publishes New Report on Mental Health Challenges Among Boys and Young Men](https://longbridge.com/en/news/286915417.md) - [09:45 ETDigital Marketing Agency CAGnite Announces Launch](https://longbridge.com/en/news/286924645.md) - [ProShare Advisors LLC Purchases 257,762 Shares of Cintas Corporation $CTAS](https://longbridge.com/en/news/286893600.md)